StreetInsider.com News Articles

Omeros shares slide following European regulatory setback for Narsoplimab

Fri, 16 Oct 2026 08:10:14 -0400

Investing.com -- Shares of Omeros Corporation (NASDAQ: OMER) retreated 4% in Friday morning trading after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) maintained a negative opinion on the marketing authorization application for its drug, narsoplimab.

Following a formal re-examination, the CHMP rejected narsoplimab as a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), reaffirming its initial negative stance from June 2026.

The regulatory decision follows a contested review process. As part of the re-examination, the CHMP convened an eight-member ad hoc expert group comprising hematologists, statisticians, transplant physicians,

Omeros shares slide following European regulatory setback for Narsoplimab

Fri, 16 Oct 2026 08:10:14 -0400

Omeros narsoplimab receives second negative EU opinion

Fri, 16 Oct 2026 06:20:18 -0400

Omeros Corporation (Nasdaq: OMER) said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the company's marketing authorization application for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), following re-examination of an original negative opinion issued in June 2026.

As part of the re-examination, CHMP convened an eight-member ad hoc expert group of hematologists, statisticians, transplant physicians, and two patient representatives. According to CHMP's final minutes, the group recommended "a review of individual patient-level data by external experts to better understand the factors associated with treatment response and survival." Omeros had

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Fri, 16 Oct 2026 06:19:00 -0400

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026.

An eight-member ad hoc expert group (AHEG) consisting of hematologists, statisticians, and transplant physicians, together with two patient representatives, was convened by CHMP as part of the re-examination process. The AHEG was charged with addressing a single, three-part question

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Fri, 16 Oct 2026 06:19:00 -0400

Omeros (OMER) Reiterated at Overweight by Cantor Fitzgerald Ahead of Potential Catalyst

Wed, 14 Oct 2026 07:16:16 -0400

Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $22.00 price target on Omeros Corp. (NASDAQ: OMER).

The analyst commented, "We're flagging a potential catalyst for OMER this week: OMER will present its Yartemlea case to CHMP today (October 14) at 10AM ET, and we expect a final opinion by the end of the week. Yartemlea is a monoclonal MASP-2 antibody for TA-TMA, and is already approved / launched in the US. Our call: we're not expecting a reversal from CHMP, but we're not writing it off either. Omeros gets another chance to make its case to CHMP after the

Form 4 OMEROS CORP For: Sep 22 Filed by: Borges David J.

Mon, 28 Sep 2026 11:50:00 -0400

si-local-file:///var/storage/secattach/20260928/27112152.html

Form 4 OMEROS CORP For: Sep 22 Filed by: Borges David J.

Thu, 24 Sep 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260924/27103263.html

Form 144 OMEROS CORP Filed by: Borges David J.

Wed, 23 Sep 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260923/27096947.html

Form 144 OMEROS CORP Filed by: Borges David J.

Tue, 22 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260922/27091250.html

Cantor Fitzgerald Upgrades Omeros Corp. (OMER) to Overweight, 'We May Have Underestimated Yartemlea'

Tue, 22 Sep 2026 06:33:52 -0400

(Updated - September 22, 2026 6:33 AM EDT)

Cantor Fitzgerald analyst Olivia Brayer upgraded Omeros Corp. (NASDAQ: OMER) from Neutral to Overweight with a price target of $22.00.

The analyst comments "We're upgrading OMER to Overweight (from Neutral) and are reinstating a PT of $22. We came away from 2Q thinking Yartemlea was having a much better launch than we expected. A month later, after doing more work on the market and talking to physicians, we're increasingly convinced this could also be a bigger drug than we appreciated."

For an analyst ratings summary and ratings history on Omeros Corp. click here. For

Cantor Fitzgerald Upgrades Omeros Corp. (OMER) to Overweight, 'We May Have Underestimated Yartemlea'

Tue, 22 Sep 2026 06:33:52 -0400

(Updated - September 22, 2026 6:33 AM EDT)

Cantor Fitzgerald analyst Olivia Brayer upgraded Omeros Corp. (NASDAQ: OMER) from Neutral to Overweight with a price target of $22.00.

For an analyst ratings summary and ratings history on Omeros Corp. click here. For

Cantor Fitzgerald Upgrades Omeros Corp. (OMER) to Overweight, 'We May Have Underestimated Yartemlea'

Tue, 22 Sep 2026 06:33:52 -0400

(Updated - September 22, 2026 6:33 AM EDT)

Cantor Fitzgerald analyst Olivia Brayer upgraded Omeros Corp. (NASDAQ: OMER) from Neutral to Overweight with a price target of $22.00.

For an analyst ratings summary and ratings history on Omeros Corp. click here. For

Cantor Fitzgerald Upgrades Omeros Corp. (OMER) to Overweight, 'We May Have Underestimated Yartemlea'

Tue, 22 Sep 2026 06:33:52 -0400

(Updated - September 22, 2026 6:33 AM EDT)

Cantor Fitzgerald analyst Olivia Brayer upgraded Omeros Corp. (NASDAQ: OMER) from Neutral to Overweight with a price target of $22.00.

For an analyst ratings summary and ratings history on Omeros Corp. click here. For

Form 144 OMEROS CORP Filed by: Cancelmo Peter B

Fri, 28 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260828/26998574.html

Form 144 OMEROS CORP Filed by: Cancelmo Peter B

Fri, 28 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260828/26998574.html

Form 4 OMEROS CORP For: Aug 26 Filed by: HANISH ARNOLD C

Fri, 28 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260828/26998527.html

Form 4 OMEROS CORP For: Aug 26 Filed by: HANISH ARNOLD C

Fri, 28 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260828/26998527.html

Form 144 OMEROS CORP Filed by: HANISH ARNOLD C

Thu, 27 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260827/26990039.html

Form 144 OMEROS CORP Filed by: HANISH ARNOLD C

Thu, 27 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260827/26990039.html

Form 144 OMEROS CORP Filed by: HANISH ARNOLD C

Wed, 26 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260826/26982001.html

Form 144 OMEROS CORP Filed by: HANISH ARNOLD C

Wed, 26 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260826/26982001.html

Form 4 OMEROS CORP For: Aug 21 Filed by: Borges David J.

Tue, 25 Aug 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260825/26975861.html

Form 4 OMEROS CORP For: Aug 21 Filed by: Borges David J.

Tue, 25 Aug 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260825/26975861.html

Form 4 OMEROS CORP For: Aug 20 Filed by: Cable Thomas J.

Fri, 21 Aug 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260821/26962587.html